angiotensin ii has been researched along with Cardiac Free Wall Rupture in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bin, J; Cao, S; Chen, B; Fu, Y; Huang, Q; Huang, X; Kitakaze, M; Liao, Y; Lu, D; Xu, D; Zhang, J | 1 |
Blankesteijn, WM; Bornstein, P; Cleutjens, JP; Crijns, HJ; Daemen, MJ; Debets, JJ; Duisters, R; Evelo, CT; Heymans, S; Janssen, BJ; Pinto, YM; Pokharel, S; Porter, JG; Schroen, B; Sharma, U; Smits, JF; van Leeuwen, RE | 1 |
2 other study(ies) available for angiotensin ii and Cardiac Free Wall Rupture
Article | Year |
---|---|
Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cells, Cultured; Fibroblasts; Growth Differentiation Factor 15; Heart Rupture; Hypoxia; Imidazoles; Male; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Peroxidase; Tetrazoles; Tumor Suppressor Protein p53 | 2014 |
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Cardiac Output, Low; Cardiomyopathies; Collagenases; Disease Progression; Enzyme Precursors; Extracellular Matrix; Gelatinases; Gene Expression; Gene Expression Profiling; Genetic Predisposition to Disease; Heart Rupture; Humans; Hypertension; Hypertrophy, Left Ventricular; Matrix Metalloproteinase 9; Metalloendopeptidases; Mice; Mice, Knockout; Myocardium; Rats; Rats, Sprague-Dawley; Renin; Stroke Volume; Thrombospondins; Up-Regulation | 2004 |